@article {Allen2021.12.06.21266509, author = {Richard J Allen and Amy Stockwell and Justin M Oldham and Beatriz Guillen-Guio and Carlos Flores and Imre Noth and Brian L Yaspan and R Gisli Jenkins and Louise V Wain and International IPF Genetics Consortium}, title = {Genome-wide association study across five cohorts identifies five novel loci associated with idiopathic pulmonary fibrosis}, elocation-id = {2021.12.06.21266509}, year = {2021}, doi = {10.1101/2021.12.06.21266509}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Idiopathic pulmonary fibrosis (IPF) is a chronic lung condition with poor survival times. We previously published a genome-wide meta-analysis of IPF risk across three studies with independent replication of associated variants in two additional studies. To maximise power and to generate more accurate effect size estimates, we performed a genome-wide meta-analysis across all five studies included in the previous IPF risk GWAS. We utilised the distribution of effect sizes across the five studies to assess the replicability of the results and identified five robust novel genetic association signals implicating mTOR signalling, telomere maintenance and spindle assembly genes in IPF risk.Competing Interest StatementA Stockwell and B Yaspan are employees of Genentech/Roche and hold stock and stock options in Roche. J Oldham reports personal fees from Boehringer Ingelheim, Genentech, United Therapeutics, AmMax Bio and Lupin pharmaceuticals unrelated to the submitted work. G Jenkins is a trustee of Action for Pulmonary Fibrosis and reports personal fees from Astra Zeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Chiesi, Daewoong, Galapagos, Galecto, GlaxoSmithKline, Heptares, NuMedii, PatientMPower, Pliant, Promedior, Redx, Resolution Therapeutics, Roche, Veracyte and Vicore.Funding StatementR Allen is an Action for Pulmonary Fibrosis Mike Bray Research Fellow. A Stockwell and B Yaspan are employees of Genentech/Roche. J Oldham reports National Institute of Health/National Heart, Lung and Blood Institute grants R56HL158935 and K23HL138190. B Guillen-Guio is supported by Wellcome Trust grant 221680/Z/20/Z. L Wain holds a GSK/British Lung Foundation Chair in Respiratory Research (C17-1). The research was partially supported by the National Institute for Health Research (NIHR) Leicester Biomedical Research Centre; the views expressed are those of the author(s) and not necessarily those of the National Health Service (NHS), the NIHR or the Department of Health. The UK and UUS studies selected controls from UK Biobank under application 648. This research used the SPECTRE High Performance Computing Facility at the University of Leicester.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research was conducted using previously published work with appropriate ethics approval. The PROFILE study (which provided samples for the UK and UUS studies) had institutional ethics approval at the University of Nottingham (NCT01134822 - ethics reference 10/H0402/2) and Royal Brompton and Harefield NHS Foundation Trust (NCT01110694 - ethics reference 10/H0720/12). Spanish samples were recruited under ethics approval by ethics committee from the Hospital Universitario N.S. de Candelaria (reference of the approval: PI-19/12). The UUS study also included individuals from clinical trials with ethics approval (ACE [NCT00957242] and PANTHER [NCT00650091]). UK samples were recruited across multiple sites with individual ethics approval (University of Edinburgh Research Ethics Committee [The Edinburgh Lung Fibrosis Molecular Endotyping (ELFMEN) Study NCT04016181] 17/ES/0075, NRES Committee South West - Southmead, Yorkshire and Humber Research Ethics Committee 08/H1304/54 and Nottingham Research Ethics Committee 09/H0403/59). For individuals recruited at the University of Chicago, consenting patients with IPF who were prospectively enrolled in the institutional review board-approved ILD registry (IRB$\#$14163A) were included. Individuals recruited at the University of Pittsburgh Medical Centre had ethics approval from the University of Pittsburgh Human Research Protection Office (reference STUDY20030223: Genetic Polymorphisms in IPF). Individuals from the COMET (NCT01071707) and Lung Tissue Research Consortium (NCT02988388) studies were also included in the Chicago study. All subjects in the Colorado study gave written informed consent as part of IRB-approved protocols for their recruitment at each site and the GWAS study was approved by the National Jewish Health IRB and Colorado Combined Institutional Review Boards (COMIRB). Subjects in the Genentech study provided written informed consent for whole-genome sequencing of their DNA. Ethical approval was provided as per the original clinical trials (INSPIRE [NCT00075998], RIFF [NCT01872689], CAPACITY [NCT00287729 and NCT00287716] and ASCEND [NCT01366209]). For the USCF cohort, sample and data collection were approved by the University of California San Francisco Committee on Human Research and all patients provided written informed consent. For the Vanderbilt cohort, the Institutional Review Boards from Vanderbilt University approved the study and all participants provided written informed consent before enrolment.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenome-wide summary statistics can be accessed at https://github.com/genomicsITER/PFgenetics. https://github.com/genomicsITER/PFgenetics}, URL = {https://www.medrxiv.org/content/early/2021/12/07/2021.12.06.21266509}, eprint = {https://www.medrxiv.org/content/early/2021/12/07/2021.12.06.21266509.full.pdf}, journal = {medRxiv} }